Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Rhea-AI Summary
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company specializing in rare and orphan diseases, has scheduled its Q2 2025 financial results release for August 7, 2025, before market opening.
The upcoming announcement will feature both financial results for the quarter ending June 30, 2025, and an operational update covering the company's key achievements and recent milestones.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, QNRX declined 12.36%, reflecting a significant negative market reaction. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $607K from the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 5.6x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
ASHBURN, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the second quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025.
The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals (QNRX) release its Q2 2025 earnings?
What period will Quoin Pharmaceuticals' Q2 2025 earnings cover?
What will be included in Quoin Pharmaceuticals' Q2 2025 earnings announcement?
What is Quoin Pharmaceuticals' (QNRX) main business focus?
